Contribute Try STAT+ Today

Rise and shine, everyone, the middle of the week is already here. And a hazy, muggy morning is unfolding here on the Pharmalot campus this morning, where the officials mascot is noisily snoozing and one of the short people is sleeping in. As for us, we are downing yet another needed cup of stimulation — candy cane is our latest experiment. Feel free to join us. As always, no prescription is required, which means no need to worry about rebates. And here are some tidbits to help you along. Have a wonderful day and keep in touch. …

Newly unsealed documents in a landmark lawsuit show the pressure within drug makers to sell opioids in the face of numerous red flags during the height of the epidemic, the Washington Post reports. The exhibits shed new light on aspects of the epidemic that have come to symbolize the magnitude of the crisis. The release of the exhibits — sworn depositions of executives, internal corporate emails, and expert reports — also reveal the ignored concerns of some employees about the huge volume of pain pills streaming across the nation.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.